Eskicorapci Saadettin Yilmaz, Guliyev Fuad, Islamoglu Ekrem, Ergen Ali, Ozen Haluk
Department of Urology, School of Medicine, Hacettepe University, Ankara, Turkey.
Int Urol Nephrol. 2007;39(1):189-95. doi: 10.1007/s11255-006-9009-5. Epub 2006 Jun 1.
To evaluate the diagnostic performance of 14-core repeat biopsy protocol and the impact of prior biopsy scheme on repeat prostate biopsy group.
211 patients had repeat biopsy using 14-core protocol consisting of 10-core peripheral zone (classical sextant+4 lateral peripheral cores) and 4-core transitional zone (TZ) biopsies. The diagnostic yield was determined both in patients who had previously undergone sextant or 10-core biopsy protocol.
Overall cancer detection rate was 25.6%. 14-core biopsy technique detected cancer in 36.1 and 18.7% of the patients who had a previous sextant biopsy and 10-core biopsy protocol, respectively (P = 0.005). Patients with and without high-grade prostatic intraepithelial neoplasia (HGPIN) in the previous sextant biopsy had 56.5 and 28.3% cancer detection rates on the subsequent extended biopsy, respectively (P = 0.017) Patients who had previous 10-core biopsy with and without HGPIN revealed 22.9 and 17.2% cancer detection rates, respectively (P = 0.465) Additional four lateral peripheral cores detected 33% (3/30) and 17% (4/24) of cancers in patients with previous sextant and 10-core biopsy, respectively. 3.7% of the patients had tumor only in the TZ and none of them had prior extended biopsy.
The yield of extended 14-core repeat biopsy protocol was higher in patients with previous negative sextant biopsy compared to the patients with previous negative 10-core biopsy. HGPIN history found on previous sextant biopsy was a strong cancer predictor on repeat biopsy; same was not true for the patients with previous 10-core biopsy. The yield of lateral peripheral cores and TZ biopsies were lower in patients with prior negative extended biopsy.
评估14针重复活检方案的诊断效能以及既往活检方案对重复前列腺活检组的影响。
211例患者采用14针方案进行重复活检,该方案包括10针外周区(经典六分区+4针外侧外周区)活检和4针移行区活检。对既往接受过六分区或10针活检方案的患者均测定诊断率。
总体癌症检出率为25.6%。14针活检技术在既往接受过六分区活检和10针活检方案的患者中分别检测出36.1%和18.7%的癌症(P=0.005)。既往六分区活检中有高级别前列腺上皮内瘤变(HGPIN)和无HGPIN的患者,在随后的扩大活检中癌症检出率分别为56.5%和28.3%(P=0.017)。既往10针活检中有HGPIN和无HGPIN的患者,癌症检出率分别为22.9%和17.2%(P=0.465)。额外的4针外侧外周区活检在既往接受过六分区活检和10针活检的患者中分别检测出33%(3/30)和17%(4/24)的癌症。3.7%的患者肿瘤仅位于移行区,且均未接受过既往扩大活检。
与既往10针活检阴性的患者相比,既往六分区活检阴性的患者采用14针重复活检方案的检出率更高。既往六分区活检中发现有HGPIN病史是重复活检时癌症的有力预测指标;既往10针活检的患者则并非如此。既往扩大活检阴性的患者,外侧外周区活检和移行区活检的检出率较低。